J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.
Brand Watch: Three companies put their impacts on nature under a microscope. Here’s what they found
Look deep into nature and then you will understand everything better.” The quote from Albert Einstein is generally deployed to highlight the intuitive interconnectedness of the natural world; but it ...
pharmaphorum11y
GSK receives offer for thrombosis brands
GSK has received an offer from South African pharma company, Aspen, and it's wholly owned subsidiary, Aspen Global Incorporated, for its thrombosis brands and Notre-Dame de Bondeville (NDB ...
UBS Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...
CNN4y
GSK plc Sponsored ADR
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...
Creative Review2y
Wolff Olins overhauls GSK’s identity
Wolff Olins has created the new brand identity for global healthcare company GSK (formerly GlaxoSmithKline), aiming to better express its focus on innovation. The agency was brought on board around 18 ...